ArticleBMC cancer2025
Testicular cancer in Latvia: incidence trends and prognostic outcomes across a 23-year study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to analyze trends in testicular cancer incidence, mortality, and survival in Latvia from 1994 to 2017. MATERIALS AND
methodsThis retrospective cohort study analyzed testicular cancer patients diagnosed in Latvia between 1994 and 2017. The population-based cancer registry recorded nearly all cases. Patients were categorized by age, tumor histology (seminoma, non-seminoma, unspecified), and disease stage according to the TNM classification system. The Joinpoint regression model was used to analyze trends in incidence, mortality. Kaplan-Meier analysis was performed to calculate 5- and 10-year cancer-specific and overall survival probabilities.
resultsDuring the study period, the age-standardized incidence rate of testicular cancer increased from 2.25 to 3.57 per 100,000, with an annual percentage change (APC) of 2.37% (95% CI: 0.78, 3.9). The incidence of both seminoma and non-seminoma increased significantly. The APC for seminoma was 3.186% (95% CI: 0.429, 5.991), while for non-seminoma, it was 4.104% (95% CI: 0.486, 52.597). The overall and cancer-specific 5-year survival probabilities in Latvia were 70.6% (95% CI: 67, 74) and 76.4% (95% CI: 73.4, 79.6), respectively. The overall and cancer-specific 10-year survival probabilities were 66% (95% CI: 62, 69) and 74.0% (95% CI: 70.8, 77.4), respectively. The 5-year overall survival rate increased by 19.8 percentage points, from 59.1% in 1994-1999 to 80.9% in 2010-2017. The observed 5-year cancer-specific survival increased by 27.4 percentage points over the same period. The mortality rate did not change significantly, with an APC of 1.32% (95% CI: -1.52 to 4.2) during this period.
conclusionsA moderate increase in testicular cancer incidence was observed in Latvia over 23 years, while the mortality rate remained stable. The 5-year relative survival improved over different time periods; yet outcomes could be further enhanced if a multidisciplinary approach to diagnostics and management had been implemented in Latvia, as in other countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.